Everest Medicines Acquires Novel SHPT Asset from Micot in $1.3B Deal

Event summary

  • Everest Medicines has licensed MT1013, a dual-targeting receptor agonist polypeptide, from Micot for commercialization in China and Asia-Pacific (excluding Japan).
  • The deal includes an upfront payment of RMB 200 million and up to RMB 1,040 million in regulatory and commercial milestone payments, totaling up to RMB 1.24 billion (approximately $1.3 billion USD).
  • MT1013 is currently in Phase III clinical trials in China, with over 50% of enrollment already achieved.
  • The asset targets Secondary Hyperparathyroidism (SHPT), a condition affecting an estimated 189.9 million people globally by 2030.

The big picture

This acquisition underscores the growing demand for innovative therapies in the renal disease space, particularly in Asia-Pacific, where the prevalence of chronic kidney disease is rapidly increasing. Everest Medicines’ move to expand its nephrology portfolio beyond IgA nephropathy signals a strategic shift towards addressing a broader range of chronic kidney diseases, leveraging its existing commercial platform to capture a larger share of a substantial market. The dual-targeting mechanism of MT1013 represents a potential therapeutic innovation, moving beyond traditional approaches to SHPT management.

What we're watching

Clinical Outcomes
The success of Everest Medicines' investment hinges on the Phase III trial results; failure to demonstrate superiority over cinacalcet could significantly impact future revenue projections.
Regulatory Approval
The speed of regulatory approval in China will be a key determinant of Everest’s ability to capitalize on the large SHPT patient population.
Commercial Execution
Everest’s existing commercial infrastructure will be tested by the need to rapidly scale distribution and marketing for MT1013 across a broad geographic region.

Related topics

Clinical Trial